Evaluating Glial Acetate Metabolism as a Biomarker of Hypoglycemic Counterregulation

NARecruitingINTERVENTIONAL
Enrollment

10

Participants

Timeline

Start Date

February 19, 2020

Primary Completion Date

June 30, 2026

Study Completion Date

September 30, 2026

Conditions
DiabetesHypoglycemia
Interventions
OTHER

hyperinsulinemic-hypoglycemic clamp

An intravenous catheter will be placed in an antecubital vein for infusion of insulin and glucose. A second catheter will be placed retrograde in a dorsal vein of the contra-lateral hand for blood withdrawal. The hand will be placed in a heating box or pad at 70°C for arterialization of venous blood. A primed infusion of regular insulin (120 mU/min/m2) will be initiated and continued for approximately 2 hours. Beginning 20 minutes prior to the start of the insulin infusion, arterialized venous blood glucose will be measured at 5 minute intervals via a Hemocue or YSI analyzer. Following initiation of insulin infusion, blood glucose will be allowed to fall to 50 mg/dL and then maintained at this level using a variable infusion of exogenous dextrose (20% solution). Our goal is to achieve steady-state (blood glucose stabilized at 50 +/- 5 mg/dL) within the first 45 minutes following the start of insulin infusion.

OTHER

13C-MRS procedure/Acetate infusion

Glial metabolism will be measured via MRS utilizing a simultaneous intravenous infusion of 13C labeled acetate. An intravenous catheter will be placed in a vein of each arm, one to infuse 13C-acetate and the other to draw blood samples

Trial Locations (1)

70808-4124

RECRUITING

Pennington Biomedical Research Center, Baton Rouge

All Listed Sponsors
lead

Pennington Biomedical Research Center

OTHER